Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Oral Testosterone Undecanoate in Hypogonadal Men
NCT01765179Phase 3Completed
- Sponsor
- Clarus Therapeutics
- Start
- Jan 2013
- Primary completion
- Jul 2013
- Modality
- Hormone, Biologic
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of testosterone undecanoate in male hypogonadism, sponsored by Clarus Therapeutics. Primary endpoint: Percentage of Treated Patients With an Average Serum Testosterone (T) Concentration (Cavg) Between 300 and 1000 ng/dL at Day 114. Started Jan 2013; status: completed.
02
Drugs
testosterone undecanoate
03
Conditions
male hypogonadism
Beyond the preview
Go deeper on NCT01765179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01765179.